CompletedPhase 2NCT05307328

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Studying OBSOLETE: Cushing syndrome

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sparrow Pharmaceuticals
Principal Investigator: Frank Czerwiec, MD
Sparrow Pharmaceuticals (info@sparrowpharma.com)
Intervention: SPI-62(drug)
Enrollment: 26 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2025

Study locations (12)

St. Joseph's Hospital and Medical Center - Barrow Neurological Institute (BNI) - Pituitary Center, Phoenix, Arizona, United States
Southwest General Healthcare Center, Fort Myers, Florida, United States
Mayo Clinic Cancer Center (MCCC) - Rochester, Rochester, Minnesota, United States
Washington University School of Medicine - Center for Advanced Medicine (CAM), St Louis, Missouri, United States
Comprehensive and Interventional Pain Management Llp, Henderson, Nevada, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Oregon Health & Science University (OHSU) - Northwest Pituitary Center, Portland, Oregon, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Medical University of Plovdiv, Plovdiv, Bulgaria
Clinical Center of Endocrinology and Gerontology, University Hospital of Endocrinology, Medical University Sofia (USHATE), Sofia, Bulgaria
Medical University of Sofia, Sofia, Bulgaria
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05307328 on ClinicalTrials.gov

Other trials for OBSOLETE: Cushing syndrome

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Cushing syndrome →

← Back to all trials